ALFA News
Straight from the exchange filing
Every announcement Lupin has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Every Lupin announcement on ALFA FilingsSee filings →Reference market data from a third-party provider, as of the most recent story. Not a valuation or a recommendation.
Lupin Ltd receives U.S. FDA approval for Phytonadione Injectable Emulsion USP, targeting a $52.3 million annual market for vitamin K deficiency treatments.
Lupin Ltd launches Formoflo-G MDI, the world's first fixed-dose triple combination inhaler for COPD in India, addressing a market of over 55 million patients.
Lupin Ltd secured tentative US FDA approval for Apixaban Oral Suspension 1.25mg/mL. The product will be manufactured at Lupin's Somerset, New Jersey facility.
Lupin Limited subsidiary VISUfarma B.V. signs ₹832 Cr deal with Visus Therapeutics to commercialize YUVEZZI in Europe, targeting the presbyopia treatment market.
Lupin Limited launches Sugammadex Injection in the US, a bioequivalent to Merck's Bridion® for surgical recovery, as the company reports 62.5% annual profit growth.
Lupin Ltd reports record FY26 revenue of ₹27,958 cr, a 23% YoY increase. US sales crossed $1.3bn while EBITDA margins hit 29.7% on complex generic launches.
Lupin Limited achieves record FY26 results with 32% Q4 revenue growth and 29.7% EBITDA margins driven by US generic exclusivity and strong India chronic sales.
